HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

CV

CapsoVision, Inc. (NASDAQ)

Healthcare — Medical Devices

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

None 1 analysts
$7.37
$-0.21 (-2.77%)
Target: $10.00 (35.7%)
Sign in to add CV to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$368.23M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-1.06
Dividend Yield-
Profit Margin-198.87%
Revenue Growth0.30%
ROE-185.09%
Debt/Equity3.90
Recommendation None
Analyst Target$10.00
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)52.1
Beta-
SMA 20-
SMA 40-
52-Week High$15.37
52-Week Low$3.43
50-Day Avg$6.87
200-Day Avg$6.42
Avg Volume149.8K
Volume161.3K

Performance Analysis

NEUTRAL

CV presents a mixed picture with both positive and negative indicators.

~ Trading at 33% of its 52-week range.
~ RSI at 52.1 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 0.3% year-over-year.
- Operating at a loss with -198.9% margin.
~ Wall Street consensus is "none" from 1 analysts.
+ Average analyst target of $10.00 implies 35.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:05 UTC

Back to Screener Export Report